Royalty Pharma Plc · NASDAQ:RPRX
Royalty Pharma — Investor Presentation (September 2023)
6 slides from Royalty Pharma's investor presentation, September 2023
Slide 1: Royalty Pharma
ROYALTY PHARMA
Slide 2: Skytrofa royalty acquisition
royalty acquisition September 2023 The Skytofa logo is a trademark owned by Ascendis Pharma
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the “Company”), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or
Slide 4: Skytrofa – addressing significant unmet patient need in GHD
Skytrofa – addressing significant unmet patient need in GHD 1 2 3 First approved once-weekly Significant need for more Opportunity for Skytrofa therapy for pediatric GHD effective and convenient to gain market share treatments Skytrofa was the first FDA approved In the first year of treatment, two o
Slide 5: Skytrofa – first approved once-weekly therapy for pediatric GHD
Skytrofa – first approved once-weekly therapy for pediatric GHD Skytrofa U.S. consensus sales projections(5) ($ in millions) • Acquired a synthetic royalty on Ascendis’ Skytrofa for pediatric patients with growth hormone deficiency (GHD) $150 million upfront payment Entitled to 9.15% royalty on
Slide 6: The long-acting hGH market consists of 3 approved therapies
The long-acting hGH market consists of 3 approved therapies Skytrofa Sogroya Nglena Marketer Ascendis Pharma Novo Nordisk Pfizer Pediatric and Pediatric FDA approval: August 2021(1) Pediatric FDA approval: April 2023(3) Pediatric FDA approval: June 2023(5) adult GHD Adult Phase 3 topline data: Q4 20
Royalty Pharma — Investor Presentation (September 2023) on 6ix